btb1 Antibody

What is BTB1 and how does it function in mitotic processes?

BTB1 (4-Chloro-2-nitro-1-(phenylsulfonyl)benzene) is a selective and ATP-competitive mitotic kinesin Kif18A inhibitor with an IC50 of 1.7 μM. It functions by reversibly inhibiting the microtubule-stimulated Kif18A ATPase activity . To utilize BTB1 in research protocols, prepare stock solutions in DMSO at concentrations of 10-20 mM, which can then be diluted to working concentrations (typically 1-10 μM) in cell culture media. When designing experiments, account for BTB1's selectivity against other mitotic kinesins by including appropriate controls. For optimal results, exposure times typically range from 4-24 hours depending on cell type and experimental endpoints.

What are the recommended applications for BUB1B/BubR1 antibodies in cell cycle research?

BUB1B/BubR1 antibodies are valuable tools for investigating spindle assembly checkpoint mechanisms, as BUB1B encodes a kinase involved in spindle checkpoint function that localizes to the kinetochore and inhibits the anaphase-promoting complex/cyclosome (APC/C) . These antibodies are validated for multiple experimental techniques:

For optimal results in detecting BUB1B in cancer samples, heat-mediated antigen retrieval in either citrate buffer (pH6) or EDTA buffer (pH8.0) is recommended prior to antibody incubation .

How should researchers validate the specificity of BUB1B antibodies?

Validation of BUB1B antibody specificity should follow a multi-step approach. Begin with Western blot analysis using positive controls (testis tissue or dividing cancer cells) where you should detect a protein of 120-130 kDa molecular weight . Next, perform peptide competition assays using the immunogen peptide (positions K26-E448 of human BUB1B for the antibody described in the search results). For functional validation, conduct siRNA knockdown experiments to demonstrate reduced antibody signal. Cross-reactivity testing should be performed against related mitotic checkpoint proteins such as BUB1, MAD1, and MAD2. Finally, immunolocalization patterns should show kinetochore-specific staining during prometaphase and metaphase but not during interphase or anaphase.

How can researchers optimize detection of BUB1B in different cancer tissue samples?

Optimizing BUB1B detection across cancer tissue samples requires tissue-specific protocol adjustments. For colon cancer tissues, heat-mediated antigen retrieval in citrate buffer (pH6) for 20 minutes followed by blocking with 10% goat serum shows optimal results . For mammary cancer tissues, EDTA buffer (pH8.0) may provide superior epitope retrieval . The concentration of 1μg/ml for the primary antibody with overnight incubation at 4°C is recommended across tissue types.

For multi-cancer studies, consider the following optimization matrix:

To quantitatively assess BUB1B expression, implement digital pathology analysis using H-score methodology (intensity × percentage positive cells) with standardized thresholds across specimen types.

What methodological approaches can be used to study the correlation between BTB1 inhibition and BUB1B function in mitotic regulation?

To investigate the interplay between BTB1 inhibition and BUB1B function in mitotic regulation, implement a multi-modal experimental design. Begin with synchronized cell populations (double thymidine block or nocodazole arrest) treated with varying concentrations of BTB1 (0.5-10 μM). Monitor BUB1B localization using immunofluorescence microscopy with anti-BUB1B antibodies at established timepoints (prometaphase, metaphase, anaphase) .

For mechanistic insights, perform co-immunoprecipitation assays to assess how BTB1 treatment affects BUB1B interactions with APC/C components. Use live-cell imaging with fluorescently-tagged BUB1B to track kinetochore dynamics under BTB1 treatment. Complement these approaches with in vitro ATPase assays comparing Kif18A and BUB1B enzymatic activities in the presence of BTB1. For comprehensive analysis, employ phospho-proteomic profiling to identify altered phosphorylation cascades after BTB1 treatment, focusing on the spindle assembly checkpoint signaling network.

How can mammalian display systems be optimized for developing high-affinity antibodies against mitotic regulators like BTB1 and BUB1B?

Optimizing mammalian display systems for developing antibodies against mitotic regulators requires integration of Bxb1 integrase technology with targeted selection strategies. Begin by constructing a landing pad in Flp-In CHO cells containing Bxb1 AttP and AttPm recombinase sites flanking a bicistronic expression cassette driven by a CMV promoter . For antibody library construction, design targeting vectors with corresponding AttB and AttBm sites flanking your antibody expression cassette, focusing on CDR randomization strategies.

For selection, implement the following multi-stage protocol:

• Initial integration of antibody libraries via RMCE using Bxb1 integrase

• Primary selection with fluorescence-activated cell sorting using labeled BTB1 or BUB1B protein

• Secondary screening with competitive binding assays to identify high-affinity binders

• Tertiary functional screening in cell-based mitotic arrest assays

To enhance biophysical properties, randomize hydrophobic surface residues that contribute to aggregation and implement next-generation sequencing to identify variants with improved characteristics . This approach has demonstrated success in reducing aggregation propensity and polyreactivity while maintaining target binding, as shown in studies with bococizumab variants.

What are the most effective experimental controls when utilizing BUB1B antibodies in cancer research?

Implementing rigorous controls for BUB1B antibody applications in cancer research is critical for valid interpretations. For immunohistochemistry, include positive controls (testis tissue which shows high BUB1B expression), negative controls (primary antibody omission), and isotype controls (matched rabbit IgG at equivalent concentration) . For mechanistic studies, employ siRNA/shRNA knockdown controls alongside rescue experiments with wild-type and kinase-dead BUB1B variants.

When analyzing BUB1B expression across cancer samples, implement the following control matrix:

Additionally, for therapeutic targeting studies, include checkpoint override controls using established inhibitors like nocodazole or taxol to distinguish BUB1B-specific effects from general mitotic perturbations.

What is the optimal protocol for evaluating potential cross-reactivity between BTB1 inhibitors and BUB1B antibody epitopes?

To systematically assess potential cross-reactivity between BTB1 inhibitors and BUB1B antibody epitopes, implement a comprehensive binding interference assay. Begin with a competition ELISA by coating plates with recombinant BUB1B protein (K26-E448 region) , then pre-incubate anti-BUB1B antibodies with varying concentrations of BTB1 (0.1-100 μM) before adding to the plate.

For cellular validation, conduct immunofluorescence microscopy with anti-BUB1B antibodies in the presence and absence of BTB1 treatment, quantifying kinetochore localization signal intensity. Complement with surface plasmon resonance studies using immobilized BUB1B antibody with BTB1 as analyte. For structural insights, implement hydrogen-deuterium exchange mass spectrometry comparing BUB1B peptide fragments with and without BTB1 presence.

Document all findings in a cross-reactivity matrix:

How can researchers integrate BTB1 inhibition studies with BUB1B antibody-based visualization techniques for live cell imaging?

Integration of BTB1 inhibition with BUB1B antibody-based visualization requires a multi-faceted approach combining chemical biology with advanced microscopy. For live-cell applications, generate cell lines stably expressing BUB1B-fluorescent protein fusions (e.g., BUB1B-mNeonGreen) using Bxb1 integrase-mediated integration for consistent expression levels . Implement a perfusion chamber system that allows for mid-experiment addition of BTB1 at defined concentrations (1-5 μM).

For optimal imaging parameters, use spinning disk confocal microscopy with temperature and CO2 control, capturing images at 1-minute intervals for at least 4 hours post-BTB1 treatment. Complement with fluorescent markers for kinetochores (CENP-A-RFP) and chromosomes (SiR-DNA). For advanced mechanistic insights, incorporate FRET-based tension sensors at kinetochores to correlate BTB1's effects on Kif18A with changes in BUB1B-dependent checkpoint signaling.

Analyze the resulting datasets using the following parameters:

What advanced bioinformatic approaches can be applied to analyze the relationship between BTB1 sensitivity and BUB1B expression across cancer datasets?

Advanced bioinformatic analysis of BTB1 sensitivity and BUB1B expression relationships requires integration of multiple data types. Begin by extracting BUB1B expression data from cancer genomics repositories (TCGA, CCLE) and correlate with available drug sensitivity databases containing kinesin inhibitor response profiles. Implement machine learning approaches (random forest, support vector machines) to identify gene signatures that predict BTB1 sensitivity, with BUB1B expression as a key feature.

For pathway-level analysis, perform gene set enrichment analysis (GSEA) comparing high versus low BUB1B-expressing tumors, focusing on cell cycle and spindle checkpoint pathways. Develop a network analysis incorporating protein-protein interaction data for BUB1B and Kif18A interactomes to identify common signaling nodes.

Present findings using interactive visualization tools with the following elements: